Bayer receives approval in Europe for pre-filled syringe to administer aflibercept (EYLEA®)
Reading, 9 April 2020 – The European Commission (EC) has granted marketing authorisation in the European Union for a pre-filled syringe (PFS) to administer aflibercept (EYLEA®) for retinal conditions. The pre-filled syringe provides physicians with a new, streamlined method of administration, which requires fewer steps to prepare for intravitreal injection than the vial. The EC decision is applicable to all 27 European Union member states as well as the UK, Iceland, Norway and Liechtenstein.1
Aflibercept is approved for five indications, including the treatment of neovascular (wet) age-related macular degeneration (wet AMD) and the treatment of visual impairment due to: macular oedema following retinal vein occlusion (RVO; branch RVO or central RVO), diabetic macular oedema (DMO and myopic choroidal neovascularisation (myopic CNV)).1 Over 1.5 million people in the UK have macular disease, over a third of these have wet AMD with nearly 40,000 new cases arising every year.2,3
Dr. Jackie Napier, Medical Director of Ophthalmology at Bayer said, “we are delighted that aflibercept is now available for use in a pre-filled syringe, in addition to the standard glass vial, enabling physicians to choose the option that works best for them, their patients and the efficiency of their clinic”.